
    
      This is a single-center, Open Label phase I clinical trial, 9 subjects planned to be
      enrolled. The subjects will be divided into low-dose group, medium-dose group and high-dose
      group.Dose CAR+ cells/kg Low 1×105 Medium 2×106 High 6×106
    
  